| Title |
Role of taxanes in advanced prostate cancer
|
|---|---|
| Published in |
Clinical and Translational Oncology, February 2016
|
| DOI | 10.1007/s12094-015-1480-y |
| Pubmed ID | |
| Authors |
J. Cassinello, J. Carballido Rodríguez, L. Antón Aparicio |
| Abstract |
Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence throughout the evolution of the disease. The taxanes, docetaxel and cabazitaxel, exert their action at multiple levels at the tumor cell: besides inhibiting the mitosis and inducing the cell death, they induce the nuclear accumulation of FOXO1, a potent nuclear factor that acts against the activation of androgen receptor inhibiting the transcription of AR-V7 variant associated with the development of resistances to abiraterone and enzalutamide. Docetaxel, as first-line therapy, and cabazitaxel, as second-line therapy, have demonstrated to increase the survival in castration-resistant prostate cancer. The results from last studies either on high-risk localized disease or on androgen-sensitive tumors demonstrate the increasing role of taxanes at earlier states of prostate cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 21% |
| Student > Master | 4 | 14% |
| Researcher | 4 | 14% |
| Student > Ph. D. Student | 4 | 14% |
| Lecturer | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 8 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Computer Science | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 12 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2016.
All research outputs
#15,356,841
of 22,844,985 outputs
Outputs from Clinical and Translational Oncology
#676
of 1,305 outputs
Outputs of similar age
#235,181
of 398,933 outputs
Outputs of similar age from Clinical and Translational Oncology
#10
of 15 outputs
Altmetric has tracked 22,844,985 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,305 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,933 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.